Alan Ray Hunter

US Patent:

20210395370, Dec 23, 2021

Filed:

Sep 2, 2021

Appl. No.:

17/465092

Inventors:

- Cambridge, GB
William K. WANG - Gaithersburg MD, US
Ambarish SHAH - Gaithersburg MD, US
Hasige SATHISH - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US

International Classification:

C07K 16/28
B01D 15/16
B01D 15/36
B01J 41/14
B01J 41/20
A61K 47/68
C07K 1/18
C07K 17/02
A61K 39/395
A61K 47/02

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.

US Patent:

20200407423, Dec 31, 2020

Filed:

Jun 15, 2020

Appl. No.:

16/901812

Inventors:

- Gaithersburg MD, US
Mariko FONSECA - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Xiangyang WANG - Gaithersburg MD, US
Liu TIE - Gaithersburg MD, US
Yiming LI - Gaithersburg MD, US

International Classification:

C07K 14/765
A61K 47/64
C07K 1/18
C07K 1/22
C07K 14/78

Abstract:

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.

US Patent:

20200231680, Jul 23, 2020

Filed:

Feb 10, 2020

Appl. No.:

16/786634

Inventors:

- Cambridge, GB
William K. WANG - Gaithersburg MD, US
Ambarish SHAH - Gaithersburg MD, US
Hasige SATHISH - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US

International Classification:

C07K 16/28
B01D 15/16
B01D 15/36
B01J 41/14
B01J 41/20
A61K 47/68
C07K 1/18
C07K 17/02
A61K 39/395
A61K 47/02

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.

US Patent:

20180371094, Dec 27, 2018

Filed:

Sep 7, 2018

Appl. No.:

16/124441

Inventors:

- Gaithersburg MD, US
William K. WANG - Gaithersburg MD, US
Ambarish SHAH - Gaithersburg MD, US
Hasige SATHISH - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US

International Classification:

C07K 16/28
A61K 47/68
B01D 15/16

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.

US Patent:

20180105575, Apr 19, 2018

Filed:

Mar 11, 2016

Appl. No.:

15/557358

Inventors:

- Gaithersburg MD, US
Mariko FONSECA - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Xiangyang WANG - Gaithersburg MD, US
Liu TIE - Gaithersburg MD, US
Yiming LI - Gaithersburg MD, US

International Classification:

C07K 14/765
C07K 1/18
C07K 1/22
C07K 14/78

Abstract:

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.

US Patent:

20170145100, May 25, 2017

Filed:

Feb 3, 2017

Appl. No.:

15/423928

Inventors:

- Gaithersburg MD, US
William K. WANG - Gaithersburg MD, US
Ambarish SHAH - Gaithersburg MD, US
Hasige SATHISH - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US

International Classification:

C07K 16/28
A61K 47/02
A61K 39/395

Abstract:

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.